DrugsNews.net

Drugs Xagena

Search results for "Apremilast"

The Food and Drug Administration ( FDA ) has approved Otezla ( Apremilast ), oral, selective inhibitor of phosphodiesterase 4 ( PDE4 ), for the treatment of patients with moderate to severe plaque pso ...


The European Commission ( EC ) has granted marketing authorisation for Otezla ( Apremilast ), an oral selective inhibitor of phosphodiesterase 4 ( PDE4 ), in two therapeutic indications: A) For the t ...